Project Details
Description
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
| Status | Active |
|---|---|
| Effective start/end date | 5/1/25 → 4/30/30 |
Funding
- NRG ONCOLOGY FOUNDATION, INC.
- NIH NATIONAL CANCER INSTITUTE
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.